Effect of unani medicine in female lower abdominal infectious problem

Effect of Sharbate Deenar in pelvic inflammatory disease- A clinical study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/03/012454

Enrollment

Registered

2018-03-09

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- pelvic inflammatory disease

Interventions

Intervention1: Cichorium intybus L-105gm,Cichorium intybus L-90gm,Rosa damascena Mill-52.5gm,Cuscuta reflexa Roxb-17.5gm,Rheum emodi Wall ex Meissn-18gm COMPARATOR AGENT- NOT APPLICABLE: sharbat will

Eligibility

Inclusion criteria

Inclusion criteria: uncomplicated PID(lower abdominal pain-bilateral and constant(VASscore 6mg/l, abnormal vaginal discharge, WBCs > or equal to 10 per HPF on saline microscopy of discharge)

Exclusion criteria

Exclusion criteria: complicated PID(dysuria,dyspareunia,pelvic pain >30 days,vomiting,fever,CRP >10,McPS > or equal to 3,p/o tuboovarian abscess and chronic PID) history of antibiotic therapy within 7 days of recruitment; delivery,abortion or gynecological surgery within the last 30 days systemic illnesses and malignancies pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
clinical improvement in- McPS score 30-70% VAS score 30-70% WBCs count less than 10 per HPF on wet mount testTimepoint: before and after treatment	—

Secondary

Measure	Time frame
Not applicableTimepoint: Not applicable	—

Countries

India

Contacts

Public ContactDr Ismath Shameem

National institute of unani medicine

dr.ismaths@gmail.com9538274583

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026